ClinicalTrials.gg
CompletedNCT04374968Updated Nov 3, 2026Results posted

Use of Blood Flow Restriction Therapy Following ACL Tear

An interventional study of Blood flood restriction cuff in Anterior Cruciate Ligament Tear, Knee Injuries and Sport Injury, sponsored by Henry Ford Health System. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Henry Ford Health System · Not applicable, Interventional, and Treatment

How we know

Updated Nov 3, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 176 studies in Anterior Cruciate Ligament Injuries with a site in United States — 44 open to participants now, 62 under way, 3 of them phase 3. Anterior Cruciate Ligament Injuries · United States.

Enrollment
85th of 152
45 · median 50
Started
2020
with 13 others
No phase
113 of 176
27 open now
Registered
89th of 176
by date
Lead sponsor
4 of 176
Henry Ford Health System

Among the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States, this one is the 85th largest by enrollment of the 152 interventional ones that give a count, is one of 14 that started in 2020, is one of 113 with no phase, and was the 89th registered.

Anterior Cruciate Ligament Injuries

627 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 193 are open to participants now.

Browse Anterior Cruciate Ligament Injuries studies →

Open to participants now

44 of the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 122 Anterior Cruciate Ligament Injuries studies recruiting now, 27 (22%) set no upper age limit and 92 (75%) stop at 75 or younger; 46 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies in Anterior Cruciate Ligament Injuries with a site in United States, or all of them as a file.
02

Study summary

Evaluating the use of peri-operative blood flow restriction therapy surrounding anterior cruciate ligament tear

Read the detailed description

The purpose of this study is to examine the effect of utilizing blood flow restriction (BFR) therapy both before and after anterior cruciate ligament reconstruction (ACLR) following a tear. BFR has been proposed to work by restricting arterial inflow leading to an oxygen depleted environment and the ability to induce muscle adaption at lower maximum repetition via reactive hyperemia. Muscle atrophy occurs following ACL tear and reconstruction. Thus, physical therapy is used in the peri-operative period to regain strength with the ultimate goal of returning to activity.

The goal of this investigation is to determine if using BFR during perioperative therapy would lead to increased and expedited strength gains. Additionally we would like to determine if BFR helps patients to pass the standard rehabilitative functional tests and return to play sooner. We will also look at patient reported outcomes metrics and pain scores to determine if BFR has a significant impact on the patient experience surrounding ACL tear and reconstruction.

03

Conditions studied

  • Anterior Cruciate Ligament Tear
  • Knee Injuries
  • Sport Injury
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ACL tear undergoing reconstruction

Exclusion criteria

Exclusion Criteria:

  • History of pulmonary embolism
  • History of deep vein thrombosis
  • Family history of PE/DVT
  • Hypercoaguable disorder
  • Multiligamentous knee injury
  • Neurovascular injury
  • Peripheral vascular disease
  • Unable to complete physical therapy
  • Unable to tolerate blood flow restriction
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    BFR Treatment

    Patients will be recruited following ACL tear and medical screening for history of DVT/PE. Patients allocated to the BFR intervention group will undergo physical therapy with the use of a blood flow restriction cuff. Rehabilitation will consist of a structured home exercise program prior to surgery. We will instruct patients on how to perform home BFR and test them in the office to ensure competence. Following surgery patients will immediately be started in physical therapy. Therapy will consist of a structured program progressing from range of motion, to strength training and then functional tests. Both arms will use the same protocol with the only difference being use of BFR.

    Device: Blood flood restriction cuff

  • No intervention
    Control

    The control arm will undergo the same pre and post operative physical therapy as the BFR group. They will undergo a structure home therapy program prior to surgery and an outpatient physical therapy program under the guidance of a therapist following surgery.

Interventions

  • DeviceBlood flood restriction cuff

    Blood flow restriction cuffs will be used as an augment to physical therapy

06

What researchers measure

Primary outcomes

  1. Quadriceps Strength in the Operative Leg

    Quadriceps strength via handheld dynamometer. Quadriceps torque generation of operative leg evaluated at Initial Clinic Visit (ICV) and Pre-op (surgery scheduled 2 weeks after ICV)

    Time frame: Change from Initial Clinic Visit to Pre-op

Secondary outcomes

  1. Patient Reported Outcome Measurement Information System

    Patient reported outcomes measurement information system score on patient physical function. PROMIS-PF: Assesses Activities of Daily Living and Capabilities. Below 30: Severe limitations, 30-40: Moderate limitations, 40-45: Mild limitations, Above 50: Greater than average physical function. Score scale (0-100) PROMIS-PI: Assesses Pain Indication. Below 55: Within normal limits of pain interference, 50-59: Mild interference, 60-69: Moderate interference, Above 70: Severe pain interference. Score scale (0-100) PROMIS-D: Measures Depressive symptoms: Below 55: Normal to slight symptoms, 55-59: Mild symptoms, 60-69: Moderate symptoms, Above 70: Severe depressive symptoms. Score scale (0-100)

    Time frame: Initial Clinic Visit

  2. Participants Reporting Pain Using the Visual Analog Scale

    Visual analog scale pain scores, scale 0-10 higher is more pain

    Time frame: Three months

  3. Quadricep Strength in Non-operated Leg

    Quadriceps torque generation of non-operative leg evaluated at Initial Clinic Visit (ICV) and Pre-op (surgery scheduled 2 weeks after ICV)

    Time frame: Change from Initial Clinic Visit to Pre-Op

07

Results

Posted Nov 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneBFR TreatmentControl
Started2322
Completed2322
Not completed00

Outcome measures

PrimaryQuadriceps Strength in the Operative Leg

Quadriceps strength via handheld dynamometer. Quadriceps torque generation of operative leg evaluated at Initial Clinic Visit (ICV) and Pre-op (surgery scheduled 2 weeks after ICV)

Time frame:
Change from Initial Clinic Visit to Pre-op
Reported as:
Mean · Nm
Quadriceps Strength in the Operative Leg
NmBFR TreatmentControl
Initial Clinic Visit76.6 ± 41.284.9 ± 35.8
Pre-Op-5.7 ± 23.9-10.7 ± 27.8
SecondaryPatient Reported Outcome Measurement Information System

Patient reported outcomes measurement information system score on patient physical function. PROMIS-PF: Assesses Activities of Daily Living and Capabilities. Below 30: Severe limitations, 30-40: Moderate limitations, 40-45: Mild limitations, Above 50: Greater than average physical function. Score scale (0-100) PROMIS-PI: Assesses Pain Indication. Below 55: Within normal limits of pain interference, 50-59: Mild interference, 60-69: Moderate interference, Above 70: Severe pain interference. Score scale (0-100) PROMIS-D: Measures Depressive symptoms: Below 55: Normal to slight symptoms, 55-59: Mild symptoms, 60-69: Moderate symptoms, Above 70: Severe depressive symptoms. Score scale (0-100)

Time frame:
Initial Clinic Visit
Reported as:
Mean · score on a scale
Patient Reported Outcome Measurement Information System
score on a scaleBFR TreatmentControl
PROMIS-PF40.9 ± 6.041.2 ± 10.4
PROMIS-PI59.2 ± 5.658.8 ± 5.6
PROMIS-D44.2 ± 8.245.4 ± 9.1
SecondaryParticipants Reporting Pain Using the Visual Analog Scale

Visual analog scale pain scores, scale 0-10 higher is more pain

Time frame:
Three months
Reported as:
Mean · score on a scale
Participants Reporting Pain Using the Visual Analog Scale
score on a scaleBFR TreatmentControl
Participants Reporting Pain Using the Visual Analog Scale2.8 ± 2.41.9 ± 2.0
SecondaryQuadricep Strength in Non-operated Leg

Quadriceps torque generation of non-operative leg evaluated at Initial Clinic Visit (ICV) and Pre-op (surgery scheduled 2 weeks after ICV)

Time frame:
Change from Initial Clinic Visit to Pre-Op
Reported as:
Mean · Nm
Quadricep Strength in Non-operated Leg
NmBFR TreatmentControl
Initial Clinic Visit109.1 ± 57.0115.9 ± 33.5
Pre-Op-24.5 ± 41.5-20.7 ± 41.5

Adverse events

Collected over Twelve Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BFR Treatment0/23 (0%)0/23 (0%)0/23 (0%)
Control0/22 (0%)0/22 (0%)0/22 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)BFR TreatmentControlTotal
Mean26.5 ± 12.027.0 ± 11.026.75 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)BFR TreatmentControlTotal
Female12820
Male111425
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)BFR TreatmentControlTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)BFR TreatmentControlTotal
United States232245
Laterality of Injury
Laterality of Injury(Participants)BFR TreatmentControlTotal
Right Leg111021
Left Leg121224
Operative Limb Length
Operative Limb Length(centimenters)BFR TreatmentControlTotal
Mean88.6 ± 7.390.4 ± 8.389.5 ± 7.8
Non-Operative Limb Length
Non-Operative Limb Length(centimenters)BFR TreatmentControlTotal
Mean88.6 ± 7.390.4 ± 8.389.5 ± 7.8
08

Study locations

1 site
  • Henry Ford Hospital
    West Bloomfield, Michigan 48332, United States
09

References and documents

Publications

  • Okoroha KR, Tramer JS, Khalil LS, Jildeh TR, Abbas MJ, Buckley PJ, Lindell C, Moutzouros V. Effects of a Perioperative Blood Flow Restriction Therapy Program on Early Quadriceps Strength and Patient-Reported Outcomes After Anterior Cruciate Ligament Reconstruction. Orthop J Sports Med. 2023 Nov 27;11(11):23259671231209694. doi: 10.1177/23259671231209694. eCollection 2023 Nov. PubMed 38035216 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in May 2022, 21 months.

Results were first posted in Nov 2026, 4 years 6 months after primary completion.

Of 279 non-industry interventional studies with no phase under Anterior Cruciate Ligament Injuries, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 70. This study's 21 months is below that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 14 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2020
First posted
May 5, 2020
StartActual
Jul 28, 2020
Primary completionActual
May 1, 2022
CompletionActual
May 1, 2022
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 3, 2026
Enrollment
50→45
Nov 3, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedQuadriceps Strength in the Operative LegTime frame: Three months → Change from Initial Clinic Visit to Pre-op
Nov 3, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38035216 ↗
Nov 3, 2026
Secondary outcomes
2 edited, 1 added, 7 removed
What changed in the outcomes
  • EditedPatient reported outcome measurement information systemReported Outcome Measurement Information SystemTime frame: Three months → Initial Clinic Visit
  • ChangedBefore Pain scoresNow Participants Reporting Pain Using the Visual Analog ScaleTime frame: three months → Three months
  • AddedQuadricep Strength in Non-operated LegTime frame: Change from Initial Clinic Visit to Pre-Op
  • RemovedQuadriceps StrengthTime frame: six months
  • RemovedKnee range of motionTime frame: three months
  • RemovedKnee range of motionTime frame: six months
  • RemovedPatient reported outcomes measurement information systemTime frame: Six months
  • Removedinternational knee documentation committee questionnaireTime frame: three months
  • Removedinternational knee documentation committee questionnaireTime frame: six months
  • RemovedPain scoresTime frame: six months
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38035216 ↗
    Enrollment 50→45
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedQuadriceps Strength in the Operative LegTime frame: Three months → Change from Initial Clinic Visit to Pre-op
    Secondary outcomes 2 edited, 1 added, 7 removed
    What changed in the outcomes
    • EditedPatient reported outcome measurement information systemReported Outcome Measurement Information SystemTime frame: Three months → Initial Clinic Visit
    • ChangedBefore Pain scoresNow Participants Reporting Pain Using the Visual Analog ScaleTime frame: three months → Three months
    • AddedQuadricep Strength in Non-operated LegTime frame: Change from Initial Clinic Visit to Pre-Op
    • RemovedQuadriceps StrengthTime frame: six months
    • RemovedKnee range of motionTime frame: three months
    • RemovedKnee range of motionTime frame: six months
    • RemovedPatient reported outcomes measurement information systemTime frame: Six months
    • Removedinternational knee documentation committee questionnaireTime frame: three months
    • Removedinternational knee documentation committee questionnaireTime frame: six months
    • RemovedPain scoresTime frame: six months
    + 3 other changes: verification date, responsible party and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04374968
Responsible party
Sponsor
First posted
May 5, 2020
Start date
Jul 28, 2020
Primary completion
May 1, 2022
Completion
May 1, 2022
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion